TR200100737T2 - Osteoprotegerin ligand aktivitesini düzenleme yöntemi - Google Patents

Osteoprotegerin ligand aktivitesini düzenleme yöntemi

Info

Publication number
TR200100737T2
TR200100737T2 TR2001/00737T TR200100737T TR200100737T2 TR 200100737 T2 TR200100737 T2 TR 200100737T2 TR 2001/00737 T TR2001/00737 T TR 2001/00737T TR 200100737 T TR200100737 T TR 200100737T TR 200100737 T2 TR200100737 T2 TR 200100737T2
Authority
TR
Turkey
Prior art keywords
opgl
nucleic acids
osteoprotegerin
useful
regulating
Prior art date
Application number
TR2001/00737T
Other languages
English (en)
Inventor
Halkier Torben
Haaning Jesper
Original Assignee
Pharmexa A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmexa A/S filed Critical Pharmexa A/S
Publication of TR200100737T2 publication Critical patent/TR200100737T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Fodder In General (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Bulus osteoprotegerin ligandinin (OPGL, TRANCE) biyolojik aktivitesini düzenleyen dolayisiyla osteoporoz gibi özelligi asiri kemik kütlesi kaybi olan hastaliklarin tedavi edilmesini/iyilestirmesini mümkün kilan yeni bir yöntem saglamaktadir. Düzenleme ihtiyaci olan bir bireyde OPGL'ye karsi bir bagisiklik tepkisinin olusturulmasiyla gerçeklestirilir. Bagisiklik tepkileri OPGL'nin imünojenik varyantlariyla klasik asilamayla veya OPGL varyantini kodlayan nükleik asitlerin nükleik asit asilamasiyla arttirilabilir. Bulus ayrica, bulusta yararli olan bilesimlerle, polipeptidlerle ve nükleik asitlerle ve ayni zamanda bunlarin hazirlanmasinda yararli olan vektörler ve dönüstürülmüs alici hücrelerle ilgilidir.
TR2001/00737T 1998-09-15 1999-09-13 Osteoprotegerin ligand aktivitesini düzenleme yöntemi TR200100737T2 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA199801164 1998-09-15
US10289698P 1998-10-02 1998-10-02

Publications (1)

Publication Number Publication Date
TR200100737T2 true TR200100737T2 (tr) 2001-07-23

Family

ID=26065320

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/00737T TR200100737T2 (tr) 1998-09-15 1999-09-13 Osteoprotegerin ligand aktivitesini düzenleme yöntemi

Country Status (24)

Country Link
US (2) US6645500B1 (tr)
EP (1) EP1114166B1 (tr)
JP (1) JP2002525060A (tr)
KR (1) KR100671036B1 (tr)
CN (1) CN1318105A (tr)
AT (1) ATE291628T1 (tr)
AU (1) AU754971B2 (tr)
CA (1) CA2343654A1 (tr)
CZ (1) CZ2001789A3 (tr)
DE (1) DE69924392T2 (tr)
EE (1) EE200100149A (tr)
ES (1) ES2239457T3 (tr)
HK (1) HK1040261A1 (tr)
HR (1) HRP20010188A2 (tr)
HU (1) HUP0103578A3 (tr)
ID (1) ID28386A (tr)
IL (2) IL141588A0 (tr)
NO (1) NO20011304L (tr)
NZ (1) NZ510508A (tr)
PL (1) PL196790B1 (tr)
PT (1) PT1114166E (tr)
SK (1) SK3062001A3 (tr)
TR (1) TR200100737T2 (tr)
WO (1) WO2000015807A1 (tr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6316408B1 (en) * 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
EP0975754B2 (en) * 1997-04-16 2016-01-06 Amgen Inc., Osteoprotegerin binding proteins and their receptors
CN1318105A (zh) * 1998-09-15 2001-10-17 M&E生物技术公司 负调节Osteoprotegerin配体活性的方法
GB9908263D0 (en) * 1999-04-13 1999-06-02 Binding Site The Limited Eliciting improved immune responses
WO2000067777A1 (en) * 1999-05-07 2000-11-16 Biofan Pty Ltd A method of prophylaxis and treatment and agents useful therefor
ATE448781T1 (de) * 1999-07-28 2009-12-15 Univ Pennsylvania Methoden zur hemmung der aktivität der osteoklasten
US6673771B1 (en) 1999-07-28 2004-01-06 The Trustees Of The University Of Pennsylvania Methods of inhibiting osteoclast activity
AU7615600A (en) * 1999-09-27 2001-04-30 Eli Lilly And Company Osteoclast differentiation factor regulatory region
AUPQ314799A0 (en) * 1999-09-29 1999-10-21 University Of Western Australia, The Bone cell factor
ES2248283T3 (es) * 2000-02-21 2006-03-16 Pharmexa A/S Nuevo procedimiento para reducir los niveles de amiloide.
CZ20022748A3 (cs) * 2000-02-21 2004-03-17 Pharmexa A/S Nová metoda regulace obsahu amyloidu
US20030103978A1 (en) * 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
DK2105449T3 (da) * 2000-02-23 2019-10-07 Amgen Inc Antagonistiske selektive bindemidler af osteoprotegerinbindende protein
JP2003534022A (ja) * 2000-05-26 2003-11-18 スミスクライン・ビーチャム・コーポレイション Ｒａｎｋリガンド介在障害の治療に有用な抗−ｒａｎｋリガンドモノクローナル抗体
AU2001288342A1 (en) * 2000-08-21 2002-03-04 Smith Kline Beecham Corporation Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
JPWO2002024228A1 (ja) * 2000-09-21 2004-01-29 株式会社先端科学技術インキュベーションセンター 破骨細胞形成を制御する方法
ATE366306T1 (de) 2000-09-22 2007-07-15 Immunex Corp Screeningverfahren für agonisten und antagonisten des rezeptoraktivators von nf-kappa b
US7128911B2 (en) 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
WO2002080955A1 (en) * 2001-03-22 2002-10-17 Barnes-Jewish Hospital Stimulation of osteogenesis using rank ligand fusion proteins
JP4921687B2 (ja) 2001-04-03 2012-04-25 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 乳中の破骨細胞分化抑制因子
PH12012502440A1 (en) 2001-06-26 2013-06-17 Amgen Inc Antibodies to opgl
MY144532A (en) * 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
US20030109444A1 (en) * 2001-10-12 2003-06-12 Jonathan Lam Bone anti-resorptive compounds
JP4336467B2 (ja) * 2001-10-15 2009-09-30 株式会社林原生物化学研究所 破骨細胞形成抑制因子の産生を調節し得る物質のスクリーニング方法
AU2003207464A1 (en) 2002-01-04 2003-07-24 Xencor Dominant negative proteins and methods thereof
US7381792B2 (en) 2002-01-04 2008-06-03 Xencor, Inc. Variants of RANKL protein
AU2003217174A1 (en) * 2002-01-04 2003-07-30 Xencor Novel variants of rankl protein
WO2003086289A2 (en) * 2002-04-05 2003-10-23 Amgen Inc. Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors
US6921538B2 (en) * 2002-05-10 2005-07-26 Allergan, Inc. Therapeutic treatments for neuropsychiatric disorders
US7462700B2 (en) 2002-12-10 2008-12-09 Schering-Plough Animal Health Corporation Canine RANKL and methods for preparing and using the same
BRPI0511751A (pt) * 2004-06-02 2008-01-02 Cytos Biotechnology Ag usos médicos de conjugados veìculos de peptìdeos de tnf não-humano
US20080107597A1 (en) * 2006-01-12 2008-05-08 Anaptys Biosciences, Inc. Isolation of antibodies that cross-react and neutralize rankl originating from multiple species
WO2008088594A2 (en) * 2007-01-12 2008-07-24 Anaptysbio, Inc. Isolation of antibodies that cross-react and neutralize rankl orginating from multiple species
CN101434656B (zh) * 2007-11-16 2011-12-14 首都医科大学 Opg-hsp70融合蛋白的制备方法及用途
EP3029061B1 (en) * 2008-06-18 2017-09-13 The Texas A&M University System Mesenchymal stem cells, compositions, and methods for treatment of cardiac tissue damage
WO2011128892A2 (en) * 2010-04-12 2011-10-20 Protea Vaccine Technologies Ltd. Modified forms of pneumococcal surface immunogenic protein b (psipb)
CN107286245B (zh) * 2016-04-11 2021-10-08 北京普纳生物科技有限公司 Pd-l1和pd-l2重组蛋白及其用途
CN107286244B (zh) * 2016-04-11 2021-10-08 北京普纳生物科技有限公司 抗免疫检查点pd-l1和pd-l2肿瘤疫苗
CN108498786A (zh) * 2018-02-13 2018-09-07 南昌大学第二附属医院 载骨保护素的缓释纳米粒及其制备方法和应用
KR102154637B1 (ko) * 2018-11-12 2020-09-10 조선대학교산학협력단 Rankl의 돌연변이체, 및 이를 포함하는 골다공증 예방 또는 치료용 약학 조성물
WO2024054566A1 (en) * 2022-09-07 2024-03-14 The Regents Of The University Of California Treatment of cancer by blockade of osteoprotegerin
KR20250118303A (ko) * 2024-01-29 2025-08-06 주식회사 아크젠바이오사이온스 Rankl의 돌연변이체 및 이를 포함하는 백신 조성물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1237764B (it) * 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
DK96493D0 (da) * 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden
DE4496393T1 (de) 1993-08-27 1996-11-21 Dow Chemical Co Verfahren zur Trennung von Enantiomeren
AU7353094A (en) * 1994-04-01 1995-10-23 University Of Utah, The Molecular cloning and expression of a gamma-interferon inducible activator of the proteasome
US6340459B1 (en) * 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
US6369027B1 (en) * 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
EP1803816A3 (en) * 1996-12-13 2007-09-26 Schering Corporation Mammalian cell surface antigens; related reagents
US6242213B1 (en) * 1996-12-23 2001-06-05 Immunex Corporation Isolated DNA molecules encoding RANK-L
US5843678A (en) * 1997-04-16 1998-12-01 Amgen Inc. Osteoprotegerin binding proteins
EP0975754B2 (en) * 1997-04-16 2016-01-06 Amgen Inc., Osteoprotegerin binding proteins and their receptors
CN1318105A (zh) * 1998-09-15 2001-10-17 M&E生物技术公司 负调节Osteoprotegerin配体活性的方法

Also Published As

Publication number Publication date
IL141588A0 (en) 2002-03-10
HK1040261A1 (zh) 2002-05-31
HUP0103578A2 (hu) 2002-01-28
NO20011304D0 (no) 2001-03-14
ID28386A (id) 2001-05-17
DE69924392D1 (de) 2005-04-28
US6645500B1 (en) 2003-11-11
EE200100149A (et) 2002-08-15
ES2239457T3 (es) 2005-09-16
ATE291628T1 (de) 2005-04-15
HUP0103578A3 (en) 2005-11-28
IL141588A (en) 2008-07-08
JP2002525060A (ja) 2002-08-13
DE69924392T2 (de) 2006-03-09
CZ2001789A3 (cs) 2001-08-15
US20040115199A1 (en) 2004-06-17
KR100671036B1 (ko) 2007-01-18
HRP20010188A2 (en) 2002-04-30
SK3062001A3 (en) 2002-02-05
WO2000015807A1 (en) 2000-03-23
EP1114166A1 (en) 2001-07-11
AU5617399A (en) 2000-04-03
EP1114166B1 (en) 2005-03-23
AU754971B2 (en) 2002-11-28
NZ510508A (en) 2005-05-27
KR20010085807A (ko) 2001-09-07
CA2343654A1 (en) 2000-03-23
NO20011304L (no) 2001-05-15
PL196790B1 (pl) 2008-01-31
PT1114166E (pt) 2005-08-31
CN1318105A (zh) 2001-10-17
PL346698A1 (en) 2002-02-25

Similar Documents

Publication Publication Date Title
TR200100737T2 (tr) Osteoprotegerin ligand aktivitesini düzenleme yöntemi
EP1005540A4 (en) IKK-BETA PROTEINS, NUCLEIC ACIDS AND METHODS
BR9507505A (pt) Molécula de dna isolada vetor de expressão recombinante célula hospedeira método para preparar um polipeptídeo que estimula uma resposta imunológica th1 em células mononucleares do sangue periférico obtidas a partir de um individuo infectado com leishmania polipeptídeo método para avaliar a capacidade de um paciente de gerar uma resposta imunológica método para melhorar uma resposta imunológica celular e/ou humoral a um antígeno de um paciente método para estimular a produção de anticorpos em um
CY1111950T1 (el) 32 ανθρωπινες εκκρινομενες πρωτεϊνες
PL1904635T3 (pl) Glikozylowana IL-7, jej wytwarzanie i zastosowania
NZ309659A (en) Composition comprising LbeIF4A and/or LmeIF4A polypeptides (Leishmania antigen) and methods for enhancing immune responses
WO1998014596A3 (en) Disease associated protein tyrosine phosphatases
CA2281895A1 (en) Ikb kinases
WO2000017222A8 (en) 31 human secreted proteins
EP1005539A4 (en) IKK-ALPHA PROTEINS, NUCLEIC ACIDS AND METHOD
EE200200323A (et) RG1 polüpeptiidi kodeeriv DNA
WO2001062891A3 (en) 207 human secreted proteins
EP1443055A3 (en) Interleukins-21 and 22
WO2000061774A3 (en) Bone morphogenic proteins
WO2000058339A3 (en) 50 human secreted proteins
MXPA05011595A (es) Composiciones de spex y metodos de uso.
WO2000043495A3 (en) 33 human secreted proteins
DK0555785T3 (da) Glat-muskel-mitogent stof og DNA, der koder herfor
WO2003052377A9 (en) 41 human secreted proteins
BR9911388A (pt) Imunógeno de somatostatina sintético para promoção de crescimento em animais de fazenda
EA200100356A1 (ru) Способ отрицательной регуляции активности лиганда остеопротегерина
FI973762A0 (fi) Ny gen
ATE556135T1 (de) Neues protein
WO2000061596A8 (en) 50 human secreted proteins
ATE479753T1 (de) Menschliches tsc403 gen